Dr. Usmani Discusses Perseus, IsKia, Data Plus More Myeloma Updates
The HemOnc Pulse
00:00
Discussion on Venetoclax Data and Personalizing Therapy for Translocation 1114 Myeloma
Discussion of clinical abstracts presented at the conference focusing on the data of a combination treatment of Venetoclax, Deratumumab, and dexamethasone for translocation 1114 disease, with a high overall response rate and complete response rate. Emphasis on personalizing therapy, excitement about long-term follow-up data, and frustration about the delay in biomarker-driven treatments.
Transcript
Play full episode
